What the Mounjaro Clinical Trials Found — and What It Means for You

Step 1, How the SURMOUNT trials were designed and who took part

The SURMOUNT programme was the clinical backbone that brought tirzepatide to the UK weight-management market. SURMOUNT-1, the pivotal trial, enrolled 2,539 adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as hypertension or high cholesterol. Participants did not have type 2 diabetes. They were randomly assigned to one of three tirzepatide doses (5mg, 10mg or 15mg) or a placebo, all alongside dietary guidance and activity support, for 72 weeks.

The trial was published in the New England Journal of Medicine (SURMOUNT-1) and is the primary evidence base for the UK licence. If you want a detailed breakdown of the numbers across each dose arm, the tirzepatide clinical trial results page walks through them systematically.

Later in the programme, SURMOUNT-2 examined people living with type 2 diabetes, and SURMOUNT-5 (published in 2025) was the first head-to-head comparison with semaglutide 2.4mg (Wegovy). That last trial matters because it is the closest thing to a direct answer on how the two medicines compare, in real patients rather than modelled estimates. If you are interested in whether a tirzepatide clinical trial near you is currently recruiting, that page sets out what to look for and how participation typically works.

Step 2, What the results actually showed, and how NICE used them

Across the dose groups in SURMOUNT-1, average weight reduction at week 72 ran from roughly 15% at 5mg to around 20–21% at the 15mg maintenance dose. Some analyses placed the 15mg figure closer to 22.5%; the figure to use confidently is "around 20–21%". These were not outlier patients, they were statistically representative of the enrolled group, and the placebo arm lost only around 3% on average, which puts the medicine's contribution in sharp relief.

NICE reviewed this evidence, along with indirect comparisons across the wider GLP-1 field, before issuing Technology Appraisal TA1026 in December 2024. The appraisal notes that indirect comparisons favour tirzepatide over semaglutide 2.4mg, a finding the SURMOUNT-5 head-to-head subsequently supported. NICE recommends tirzepatide for adults with a BMI of 35 or above and at least one weight-related comorbidity, with thresholds lowered by 2.5 kg/m² for some ethnic backgrounds. Those criteria apply to NHS access; the private licensed eligibility criteria are set by the medicine's SmPC, which covers BMI from 27 with a qualifying condition or 30 without.

The trials also assessed cardiovascular markers, blood glucose, blood pressure and waist circumference, all moved in a favourable direction. If you would like to understand what the Mounjaro clinical name refers to and how the branding relates to the molecule studied in these trials, that page explains the relationship clearly. Weight loss alone was not the only measured outcome.

Step 3, The trial medicine versus the medicine you receive

A question our prescribers hear regularly: is the version used in the trials the same as what is dispensed today? Yes. The tirzepatide in the SURMOUNT programme is the same active molecule as in the UK-licensed Mounjaro KwikPen. Each pre-filled pen contains four weekly doses, and treatment starts at 2.5mg, a tolerability step whose job is to settle your system before the dose is titrated upward by the prescriber.

The pen itself arrives refrigerated, packed discreetly in plain unbranded packaging via DPD tracked delivery, the tracking link lands on your phone before it reaches your door. Storage from that point follows the SmPC's instructions, which the Mounjaro treatment page summarises alongside the full prescribing context. For the manufacturer's own clinical perspective, Eli Lilly's tirzepatide clinical trial programme is covered separately.

One practical note: trial participants were supported with regular dietary and lifestyle contact throughout. The evidence is built on that combined approach, not the medicine in isolation, which is why aftercare matters alongside the prescription. You can read more about what a Mounjaro clinical trial involves, including how the SURMOUNT studies were structured and what participants experienced across the programme.

Step 4, What the trials do not tell you, and where clinical assessment fills the gap

Clinical trials answer population-level questions with careful precision. They cannot tell any individual person how much weight they will lose, or whether tirzepatide is the right choice given their specific history, medications and circumstances. SURMOUNT-1 excluded people with a history of pancreatitis, certain gastrointestinal conditions, and medullary thyroid carcinoma, exclusions that exist in the licence for good reason.

Side effects in the trials were predominantly gastrointestinal: nausea, diarrhoea, constipation and indigestion were the most common, typically most noticeable around a dose increase and settling over days to a couple of weeks for most participants. The NHS tirzepatide medicines page lists these in patient-facing language and is worth reading before you start.

That translation from trial evidence to individual suitability is exactly what a prescriber does. If you are exploring whether Mounjaro could be appropriate for you, the free consultation at nume is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. Take a look at the broader range of weight-loss treatment options if you want to compare approaches before deciding. Check your eligibility when you're ready.